Want to see HK:0911 full AI Analyst Report?
Qianhai Health Holdings Ltd. (0911) AI Stock Analysis
Top Page
Qianhai Health Holdings Ltd.
(HKEX:0911)
The score is driven primarily by improved financial performance and low balance-sheet risk (turnaround to positive earnings and stronger cash flow, with minimal leverage). However, the overall rating is held back by very weak technical momentum (below major moving averages with negative MACD and oversold indicators) and only moderate valuation support (P/E ~15 with no dividend yield data).
Qianhai Health Holdings Ltd. (0911) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 53.38M
- Dividend Yield
- ―
- Average Volume (3M)
- 63.27K
- Price to Earnings (P/E)
- 13.3
- Beta (1Y)
- 0.06
- Revenue Growth
- -18.16%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 19
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Qianhai Health Holdings Ltd. Business Overview & Revenue Model
Company Description
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Ca...
Qianhai Health Holdings Ltd. Financial Statement Overview
Summary
Financials show a clear turnaround: profitability returned in 2024–2025 and operating profit is positive, while cash generation strengthened materially in 2025 (positive operating and free cash flow). The balance sheet is a major positive with extremely low leverage and a large equity base. Offsetting this, profitability remains very thin (low gross and net margins) and the business has shown multi-year volatility, making the recovery somewhat fragile.
Income Statement
58NeutralBalance Sheet
84Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 453.03M | 677.12M | 519.70M | 961.29M | 1.96B | 283.40M |
| Gross Profit | 15.82M | 22.26M | 29.67M | -35.60M | 76.48M | 16.04M |
| EBITDA | 5.29M | 7.19M | 16.32M | -50.23M | -231.24M | 2.06M |
| Net Income | 4.01M | 5.94M | 1.31M | -52.70M | -233.70M | -888.00K |
Balance Sheet | ||||||
| Total Assets | 441.43M | 408.39M | 407.31M | 478.12M | 534.43M | 738.63M |
| Cash, Cash Equivalents and Short-Term Investments | 17.88M | 61.38M | 23.51M | 19.52M | 1.64M | 2.47M |
| Total Debt | 107.00K | 424.00K | 1.03M | 487.00K | 1.19M | 7.83M |
| Total Liabilities | 47.39M | 17.19M | 21.74M | 94.00M | 97.73M | 68.09M |
| Stockholders Equity | 394.05M | 391.20M | 385.57M | 384.11M | 436.70M | 670.53M |
Cash Flow | ||||||
| Free Cash Flow | -8.64M | 38.78M | 4.19M | 857.00K | -5.26M | -44.19M |
| Operating Cash Flow | -8.64M | 38.80M | 4.20M | 857.00K | -5.26M | -44.18M |
| Investing Cash Flow | -3,000 | -14.00K | 246.00K | 17.77M | 12.34M | 46.84M |
| Financing Cash Flow | -648.00K | -648.00K | -712.00K | -743.00K | -7.91M | -16.56M |
Qianhai Health Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Negative. The current price of 0.32 is below the 20-day moving average (MA) of 0.35, below the 50-day MA of 0.41, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 28.04 is Positive, neither overbought nor oversold. The STOCH value of 5.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0911.
Qianhai Health Holdings Ltd. Peers Comparison
Overall Rating
HK:263370Outperform- HK:091161Neutral
HK:089758.6Neutral
HK:085854Neutral
HK:045544Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2633 | 70Outperform | HKD 1.78B | 6.19 | 13.26% | 9.67% | -0.47% | -0.40% |
| HK:0911 | 61Neutral | HKD 53.38M | 13.29 | 1.02% | ― | -18.16% | ― |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0455 | 44Neutral | HKD 191.35M | -2.73 | -14.55% | ― | 12.89% | -2.56% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0911 | Qianhai Health Holdings Ltd. | 0.32 | -0.03 | -7.35% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0455 | Tianda Pharmaceuticals Ltd. | 0.09 | -0.05 | -34.07% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.94 | -0.42 | -30.74% |
Qianhai Health Holdings Ltd. Corporate Events
Qianhai Health Shifts Hong Kong Principal Office to Causeway Bay
Qianhai Health Holdings Limited has announced a change to its principal place of business in Hong Kong, which will move to Room 1622, 16/F, Leighton Centre, 77 Leighton Road, Causeway Bay, effective 22 September 2026. The company emphasized that its...
Qianhai Health’s Interim Profit Holds Up Despite Sharp Revenue Drop
Qianhai Health Holdings reported unaudited interim revenue of HK$116.76 million for the six months ended 30 June 2026, down sharply from HK$340.85 million a year earlier, with gross profit falling to HK$7.71 million from HK$14.16 million as cost of s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 22, 2026